Pulsenmore, which trades in Tel Aviv and on Nasdaq, surged sharply on Wednesday after announcing a new U.S. partnership. The stock jumped 220% in Tel Aviv and 92% on Nasdaq, then fell more than 40% in Tel Aviv on Thursday as expected after the spike. The rally followed a strategic agreement with Ouma Health, an American telemedicine company that provides virtual pregnancy care in all 50 U.S. states.
Under the deal, Pulsenmore’s home ultrasound technology will be integrated into Ouma’s care model. That gives the Israeli company access to an existing framework of insurance coverage, reimbursement and clinical care, rather than another limited pilot arrangement. Pulsenmore said the partnership is especially important because it may spare the company from seeking state by state approvals in the U.S. for interpreting ultrasound results.
Pulsenmore was founded in 2014 by CEO Elazar Sonnenschein, an electrical engineering PhD and ultrasound specialist who previously founded Medigus. He owns 29% of the company. Its Pulsenmore ES device lets pregnant women perform ultrasound scans at home using a phone attached to a special cradle that transmits data, either through an app or with remote medical guidance. The product is aimed mainly at high-risk pregnancies that need frequent monitoring without repeated clinic or hospital visits.
The company went public in Tel Aviv in 2021 during the height of the “dream companies” wave at a valuation of 670 million to 733 million shekels, and its share later lost more than 90% of its value. It was also listed on Nasdaq in early 2026 and had fallen another 40% before the latest jump. Pulsenmore’s earlier major partnership with General Electric became contentious after GE invested $21 million in June 2022, then canceled a promised additional investment in September 2023 and later withdrew an order for 15,000 systems over technical issues tied to iPhone compatibility. The dispute ended in an August settlement that removed GE’s exclusivity in the U.S. and Japan, while keeping it as a non-exclusive distributor until June 2029. In November 2025, Pulsenmore also won FDA De Novo clearance after a clinical trial at four leading U.S. medical centers, a milestone that lifted the stock about 33% at the time. Sonnenschein told ynet that the FDA approval opened the way for U.S. commercial activity and that the Ouma deal can bring ultrasound beyond the clinic and into existing virtual care pathways. He also said about 35% of U.S. counties are considered “maternal care deserts.”
